269 related articles for article (PubMed ID: 18775121)
1. Pharmacologic modulation of ACE2 expression.
Soler MJ; Barrios C; Oliva R; Batlle D
Curr Hypertens Rep; 2008 Oct; 10(5):410-4. PubMed ID: 18775121
[TBL] [Abstract][Full Text] [Related]
2. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy.
Bradford CN; Ely DR; Raizada MK
Curr Hypertens Rep; 2010 Aug; 12(4):212-9. PubMed ID: 20556668
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme 2: possible role in hypertension and kidney disease.
Wysocki J; González-Pacheco FR; Batlle D
Curr Hypertens Rep; 2008 Feb; 10(1):70-7. PubMed ID: 18367030
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
5. ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.
Snyder EM; Johnson BD
Pharmacogenomics; 2020 Jul; 21(10):695-703. PubMed ID: 32501190
[TBL] [Abstract][Full Text] [Related]
6. ACE2 of the heart: From angiotensin I to angiotensin (1-7).
Keidar S; Kaplan M; Gamliel-Lazarovich A
Cardiovasc Res; 2007 Feb; 73(3):463-9. PubMed ID: 17049503
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.
Jessup JA; Gallagher PE; Averill DB; Brosnihan KB; Tallant EA; Chappell MC; Ferrario CM
Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2166-72. PubMed ID: 16766648
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
Costantino S; Millozzi F; Scarlata S
Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
[No Abstract] [Full Text] [Related]
9. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice.
Xia H; Feng Y; Obr TD; Hickman PJ; Lazartigues E
Hypertension; 2009 Feb; 53(2):210-6. PubMed ID: 19124678
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.
Ondetti MA; Cushman DW
J Med Chem; 1981 Apr; 24(4):355-61. PubMed ID: 6267277
[No Abstract] [Full Text] [Related]
11. [The renin-angiotensin system in hypertension and in cardiovascular and renal diseases: highlights of the World Congress of Nephrology 2009]].
Romet M
Nephrol Ther; 2010 Jan; 6 Spec No 1():H10-3. PubMed ID: 20129455
[No Abstract] [Full Text] [Related]
12. Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs?: a systematic review of pharmacogenomics in the Renin-Angiotensin system.
Konoshita T;
Curr Hypertens Rep; 2011 Oct; 13(5):356-61. PubMed ID: 21562941
[TBL] [Abstract][Full Text] [Related]
13. Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension.
Xia H; Sriramula S; Chhabra KH; Lazartigues E
Circ Res; 2013 Oct; 113(9):1087-1096. PubMed ID: 24014829
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
15. [spACE, the last frontier? Renin inhibition in hypertension].
Villa L
G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
[No Abstract] [Full Text] [Related]
16. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
17. A vaccine for hypertension.
Ménard J
J Hypertens; 2007 Jan; 25(1):41-6. PubMed ID: 17143170
[No Abstract] [Full Text] [Related]
18. The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
Manolis AS; Manolis TA; Manolis AA; Melita H
J Cardiovasc Pharmacol; 2020 Oct; 76(4):397-406. PubMed ID: 32769760
[TBL] [Abstract][Full Text] [Related]
19. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
[TBL] [Abstract][Full Text] [Related]
20. Association of renin-angiotensin system gene polymorphisms with antihypertensive responses to angiotensin-converting enzyme inhibition or angiotensin receptor blockade.
Stergiou GS; Efstathiou SP; Inglis GC; Connell JM; McInnes GT; Mountokalakis TD
J Hum Hypertens; 2005 Dec; 19(12):971-4. PubMed ID: 16049518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
